Navigation Links
Immunodeficient patients with secondary lung disease benefit from combined chemotherapy
Date:8/30/2012

A team of researchers at the Medical College of Wisconsin and Children's Hospital of Wisconsin Research Institute defined a new treatment for a potentially fatal lung disease in patients with a primary immunodeficiency known as common variable immunodeficiency (CVID).The findings are published in the Journal of Clinical Immunology.

Common variable immunodeficiency (CVID) is the most common primary immunodeficiency that requires regular treatment with medication, specifically immunoglobulin (antibodies) replacement therapy. With immunoglobulin therapy, deaths from infection in patients with CVID have decreased and deaths due to non-infectious complications have increased. One of the most frequent causes of death now in CVID is a lung disease known as granulomatous-lymphocytic interstitial lung disease (GLILD). In GLILD, white blood cells abnormally accumulate in the lung, which leads to a progressive decline in lung function and, eventually, respiratory failure. The researchers evaluated patients with GLILD to see if rituximab and azathioprine (combination chemotherapy) would improve pulmonary function and/or radiographic abnormalities by killing these white blood cells in the lung.

"The most common medication used for GLILD are corticosteroids but in our hands this type of medication did not clear the disease. Therefore, we designed therapy aimed at killing the specific type of lymphocytes, B cells and T cells, we found in abnormal numbers in the lung biopsies we examined. We reasoned if we killed the lymphocytes in the lung, lung function and radiographic abnormalities would both improve, which is what we found." said John M. Routes, M.D., professor and chief of asthma, allergy and immunology at the Medical College of Wisconsin (MCW), medical director of allergy/clinical immunology at Children's Hospital and researcher at the Research Institute.


'/>"/>

Contact: Maureen Mack
mmack@mcw.edu
414-955-4700
Medical College of Wisconsin
Source:Eurekalert

Page: 1

Related medicine news :

1. Study pinpoints malignant mesothelioma patients likely to benefit from drug pemetrexed
2. Mayo Clinic: Diabetes can be controlled in patients after pancreas removal
3. Confusion Over Diabetes Types Adds to Patients Woes
4. TAVI restricted to very old or very sick patients
5. Mayo study: Exercise can help cancer patients, but few oncologists suggest it
6. Exploring exercise benefits for breast cancer patients
7. Not all lung cancer patients who could benefit from crizotinib are identified by FDA-approved test
8. Early Stenting Best for Some Heart Patients: Study
9. Global platelet reactivity identifies high risk ACS patients
10. Global platelet reactivity and high risk ACS patients
11. TAVI improves quality of life in patients with severe aortic stenosis for at least 1 year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Wells Pharmacy ... enhancement of their 503A compounding pharmacy located in Ocala, Florida. , Meeting ... and patients throughout the United States for high-quality human anti-aging and wellness ...
(Date:1/19/2017)... , ... January 19, 2017 , ... WhoHaha , ... up with the American Heart Association (AHA) to produce a three-part video series that ... will debut as part of the launch of AHA’s Healthy For Good™ movement, which ...
(Date:1/19/2017)... Somerset, N.J. (PRWEB) , ... January 19, 2017 ... ... advanced delivery technologies and development solutions for drugs, biologics and consumer health products, ... Medicines with Lipids,” with Gattefossé, the leader in innovative excipients and drug delivery ...
(Date:1/19/2017)... ... January 19, 2017 , ... In 2009, ... fillers that resulted in severe facial disfiguration. After four frightening years of isolation ... at UCLA Medical Center, who removed the substances in a partial facial transplant ...
(Date:1/19/2017)... ... January 19, 2017 , ... Ultimate Medical Academy (UMA) ... are passionate about making a difference in the lives of the next generation ... a nonprofit healthcare educational institution, has more than 30,000 alumni and employs more ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... January 19, 2017 Pfizer ... the Milner Therapeutics Consortium   Major ... Cambridge   The Milner ... PFE ) as a partner to the Milner Therapeutics ... enables the efficient transfer of materials between industry and ...
(Date:1/19/2017)... 18, 2017  ViewRay, Inc. (Nasdaq: ... only clinical MRI-guided radiation therapy system, announced today that ... $26.1 million through a private placement of its ... the financing and was joined by certain of ... Kearny Venture Partners, and an additional new institutional ...
(Date:1/19/2017)... Jan. 18, 2017 The Academy of ... Drug Administration (FDA) for its release today of ... health decision makers can proactively share clinical and ... well as emerging therapies awaiting FDA approval. ... recommendations that AMCP developed during two multi-stakeholder meetings ...
Breaking Medicine Technology: